|
Adenoma
|
0.030 |
AlteredExpression
|
group |
LHGDN |
Overexpression of p16 and CDK4 in the cytoplasm, as well as loss expression of p16 in the nucleus might be important in the evolution of colorectal carcinoma from adenoma and, of adenoma from normal epithelia.
|
17072968 |
2006 |
|
Adenoma
|
0.030 |
Biomarker
|
group |
BEFREE |
Most carcinomas showed stronger p16 and CDK4 immunostaining in the cytoplasm than the adenomas or the adjacent normal mucosa.
|
14562378 |
2003 |
|
Adenoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Overexpression of p16 and CDK4 in the cytoplasm, as well as loss expression of p16 in the nucleus might be important in the evolution of colorectal carcinoma from adenoma and, of adenoma from normal epithelia.
|
17072968 |
2006 |
|
Adenomatous Polyposis Coli
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
DNA was extracted, modified with sodium bisulfite, and subjected to real-time quantitative, methylation-specific polymerase chain reaction analysis for the following genes: adenomatous polyposis coli (APC); cadherin 1, type 1, E-cadherin (epithelial) (CDH1); estrogen receptor 1 (ESR1); cytokine high in normal 1 (HIN1); hyperplastic polyposis protein 1 (HPP1); O-6 methylguanine-DNA methyltransferase (MGMT); neural epidermal growth factor-like 1 (NELL1); splicing factor 3B, 14-kDa subunit (p14); cyclin-dependent kinase (CDK) inhibitor 2B (inhibits CDK4) (p15); retinoic acid receptor beta (RARβ); somatostatin (SST); tachykinin, precursor 1 (TAC1); and tissue inhibitor of metalloproteinase (TIMP) metallopeptidase inhibitor 3 (TIMP3).
|
20572039 |
2010 |
|
Adrenocortical carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these data underline the impact of CDK4 and CDK6 inhibitors in treating adrenocortical carcinomas.
|
29283884 |
2017 |
|
Adult Acute Lymphocytic Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings provide novel insight into interphase microtubule function and, from a therapy standpoint, strongly caution against combining microtubule targeting agents and CDK4/6 inhibitors for ALL.
|
29995568 |
2018 |
|
Adult Acute Lymphocytic Leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Proteins of the p16(INK4A)/CDK4-6/pRb pathway and telomerase activity were analyzed in 123 adult B-cell precursor (BCP) ALL cases included in the GRAALL/GRAAPH trials.
|
25675863 |
2015 |
|
Adult B Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
By gene expression analysis performed in a cohort of childhood patients affected by B-acute lymphoblastic leukemia (B-ALL) we found that both CDK4 and CDK6 are highly expressed.
|
29408328 |
2018 |
|
Adult Burkitt Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The novel mutation patterns identified here imply rational use of DNA-damaging chemotherapy in some patients with BL and targeted agents such as the CDK4/6 inhibitor palbociclib in others, whereas the importance of BCR signaling in BL strengthens the potential benefit of inhibitors for PI3K, Syk, and Src family kinases among these patients.
|
30617194 |
2019 |
|
Adult Burkitt Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We found that protease-resistant galectin-9, hG9NC(null), but not galectin-1 or -8, prevented cell growth of malignant B cells, such as Burkitt lymphoma (BL) and Hodgkin lymphoma (HL). beta-galactoside binding was essential for galectin-9-induced cell growth suppression. hG9NC(null) induced cell cycle arrest by reducing the expression of cyclin D1, D2, B1, Cdk4, Cdc25C and c-Myc, and apoptosis by reducing the expression of XIAP, c-IAP2 and survivin.
|
18503581 |
2008 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we analysed 34 de novo diffuse large B cell lymphoma (DLCL) from a population-based lymphoma registry for alterations of the RB1 pathway at the genetic (RB1 and CDK4) and protein (pRb, cyclin D1, cyclin D3, CDK4, and E2F-1) level.
|
10803523 |
2000 |
|
Adult Diffuse Large Cell Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Also, we conducted CDK4 promoter assay in K562 cells and studied the protein expression of CDK4 in Wayne State University (WSU)-follicular small cleaved cell lymphoma (FSCCL), WSU-diffuse large cell lymphoma, and WSU-Waldenström's macroglobulinemia (WM) lymphoma cells.
|
28989285 |
2017 |
|
Adult Extraskeletal Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Both ESOS with a low-grade component showed co-amplification for MDM2 and CDK4.
|
29489027 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings demonstrate that the activation of c-Met/TrkA-B pathways is a novel mechanism involved in therapeutic resistance of GBM to CDK4/6 inhibition and that dual inhibition of c-Met/Trk with CDK4/6 should be considered in future clinical trials.<b>Significance:</b> CDK4/6 inhibition in glioblastoma activates the c-Met and TrkA-B pathways mediated by NF-κB and can be reversed by a dual c-Met/Trk inhibitor.<i></i>.
|
29844123 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Characterization of diverse immune responses will facilitate patient stratification and improve personalized immunotherapy in the future.<b>Significance:</b> This study utilizes a computational approach to characterize the immune environments in glioblastoma and shows that glioblastoma immune microenvironments can be classified into three major subgroups, which are linked to typical glioblastoma alterations such as IDH mutation, NF1 inactivation, and CDK4-MARCH9 locus amplification.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/19/5574/F1.large.jpg <i></i>.
|
29921698 |
2018 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pharmacological inhibition or small interfering NTSR1 treatment blocked glioblastoma cell cycle progression in the G1 phase with a concomitantly decreased expression of CDK6, CDK4, and c-Myc.
|
26180082 |
2016 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibition is more active against the glioblastoma proneural subtype.
|
28903422 |
2017 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LTS GB showed frequent chromosomal gains in 4q12 (platelet derived growth factor receptor alpha and KIT) and 12q14.1 (cyclin-dependent kinase 4), and deletion in 19q13.33 (BAX, branched chain amino-acid transaminase 2, and cluster of differentiation 33).
|
27932423 |
2017 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression.
|
28368413 |
2017 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
On real cancer data, pathTiMEx recapitulates previous knowledge on tumorigenesis, such as the temporal order among pathways which include APC, KRAS, and TP53 in colorectal cancer, while also proposing new biological hypotheses, such as the existence of a single early causal event consisting of the amplification of CDK4 and the deletion of CDKN2A in glioblastoma. pathTiMEx is available as an R package.
|
27936934 |
2017 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Gene expression profiles of three glioma stem cell line samples, three normal astrocyte samples, three astrocyte overexpressing 4 iPSC-inducing and oncogenic factors (myc(T58A), OCT-4, p53DD, and H-Ras(G12V)) samples, three astrocyte overexpressing 7 iPSC-inducing and oncogenic factors (OCT4, H-Ras(G12V), myc(T58A), p53DD, cyclin D1, CDK4(RC24) and hTERT) samples and three glioblastoma cell line samples were downloaded from the ArrayExpress database (accession: E-MTAB-4771).
|
28952134 |
2017 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
|
28814434 |
2017 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
|
31307887 |
2019 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene expression-based prediction of genomic copy number aberrations in the chromosomal region 12q13 to 12q15 that is flanked by MDM2 and CDK4 identified Wnt inhibitory factor 1 (WIF1) as a candidate tumor suppressor gene in glioblastoma.
|
21642372 |
2011 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
|
22711607 |
2012 |